$1.65
-0.10 (-5.71%)
Open$1.74
Previous Close$1.75
Day High$1.79
Day Low$1.65
52W High$13.20
52W Low$1.63
Volume—
Avg Volume70.4K
Market Cap2.78M
P/E Ratio—
EPS$-5.33
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,104.8% upside
Current
$1.65
$1.65
Target
$19.88
$19.88
$13.54
$19.88 avg
$24.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 200.3K | 198.3K | 653.1K |
| Net Income | -11,746,619 | -10,468,320 | 116.0K |
| Profit Margin | -5,863.7% | -5,570.5% | 17.8% |
| EBITDA | -12,004,687 | -11,292,655 | 172.6K |
| Free Cash Flow | — | — | 101.3K |
| Rev Growth | +1.0% | +1.0% | -9.1% |
| Debt/Equity | — | — | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |